A Phase 1 interventional study of PfSPZ Challenge and Palcebo in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-01.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Malaria with a site in Netherlands — none open to participants now, none under way, none of them phase 3. Malaria · Netherlands.
Among the 24 studies in Malaria with a site in Netherlands, this one is the 6th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 in phase 1, and was the 22nd registered.
1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →None of the 24 studies in Malaria with a site in Netherlands is open now. The open studies under Malaria, anywhere →
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 4 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2020.
This study's enrollment of 39 is below the median of 252 across 939 interventional studies indexed under Malaria.
Median enrollment 25 across the 23 interventional studies, 837 across the 1 observational. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
Merck KGaA, Darmstadt, Germany has 3 studies filed under Malaria — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Malaria with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study was to assess the chemoprophylactic activity and dose-exposure-response relationship of single oral dose of M5717 administered after direct intravenous inoculation (DVI) of Plasmodium falciparum sporozoite (PfSPZ) challenge in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single dose of placebo matched to M5717 capsule on Day 1 after 2 hours of Plasmodium falciparum Sporozoite (PfSPZ) (3200 sporozoites per injection) intravenous (IV) inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: Palcebo
Participants received single dose of M5717 30 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: M5717 30 mg
Participants received single dose of M5717 60 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: M5717 60 mg
Participants received single dose of M5717 80 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: M5717 80 mg
Participants received single dose of M5717 100 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: M5717 100 mg
Participants received single dose of M5717 200 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: M5717 200 mg
Participants received single dose of placebo matched to M5717 capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: Placebo
Participants received single dose of M5717 60 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: M5717 60 mg
Participants received single dose of M5717 100 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: M5717 100 mg
Participants received single dose of M5717 200 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
Biological: PfSPZ Challenge · Drug: M5717 200 mg
Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
Participants received 30 mg single oral dose of M5717 capsule on Day 1.
Participants received 60 mg single oral dose of M5717 capsule on Day 1.
Participants received 80 mg single oral dose of M5717 capsule on Day 1.
Participants received 100 mg single oral dose of M5717 capsule on Day 1.
Participants received 200 mg single oral dose of M5717 capsule on Day 1.
Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
Participants received 60 mg single oral dose of M5717 capsule on Day 5.
Participants received 100 mg single oral dose of M5717 capsule on Day 5.
Participants received 200 mg single oral dose of M5717 capsule on Day 5.
Early Liver Stage: Number of Participants Over Time With Positive Parasitemia
Number of participants with positive parasitemia defined as first positive quantitative polymerase chain reaction (qPCR) outcome equal or greater than 100 asexual parasites per milliliter (mL) of blood within 28 days of PfSPZ challenge.
Time frame: Early Liver Stage: From Day 1 up to Day 28
Late Liver Stage: Number of Participants Over Time With Positive Parasitemia
Number of participants with positive parasitemia defined as first positive quantitative polymerase chain reaction (qPCR) outcome equal or greater than 100 asexual parasites per milliliter (mL) of blood within 28 days of PfSPZ challenge.
Time frame: Late Liver Stage: From Day 5 up to Day 32
Early Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)
Time to first positive parasitemia was defined as the time (i.e., number of days) from the PfSPZ DVI (i.e., date of DVI PfSPZ) to the first qPCR outcome greater than or equal to (\>=) 100 asexual parasites per milliliter (mL) of blood.
Time frame: Early Liver Stage: From Day 1 up to Day 28
Late Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)
Time to first positive parasitemia was defined as the time (i.e., number of days) from the PfSPZ DVI (i.e., date of DVI PfSPZ) to the first qPCR outcome greater than or equal to (\>=) 100 asexual parasites per milliliter (mL) of blood.
Time frame: Late Liver Stage: From Day 5 up to Day 32
Early Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth
Documented blood stage parasite growth was defined as an increase of qPCR measured asexual parasites per mL compared to the first parasitemia measurement, within 28 days of PfSPZ DVI.
Time frame: Early Liver Stage: From Day 1 up to Day 28
Late Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth
Documented blood stage parasite growth was defined as an increase of qPCR measured asexual parasites per mL compared to the first parasitemia measurement, within 28 days of PfSPZ DVI.
Time frame: Late Liver Stage: From Day 5 up to Day 32
Early Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score
The malaria clinical score consisted of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension. The minimum score was 0 (no symptoms) and the maximum score was 42 (maximum symptoms). Total scores are reported here.
Time frame: Early Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26 and 28
Late Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score
The malaria clinical score consisted of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension. The minimum score was 0 (no symptoms) and the maximum score was 42 (maximum symptoms). Total scores are reported here.
Time frame: Late Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30 and 32
Dose Exposure Response Relationship of M5717 Assessed by Logistic Regression Model
Exposure efficacy relationship was analyzed using logistic regression model. Different exposure matrices (AUC0-24, AUC0-168, AUC0-inf, C24 and C168) were analyzed using logistic regression model.
Time frame: From Day 5 up to Day 32
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE was defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment-related TEAEs: reasonably related to study intervention.
Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Based on Severity
Severity of adverse events (AE) were assessed by the investigator per the Qualitative Toxicity Scale. Grade 1= Mild, Grade 2=Moderate, Grade 3=Severe. The number of participants that experienced at least one solicited local TEAE were summarized by grade. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of participants with Grade=1, Grade=2 and 3 were reported.
Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
Laboratory assessments included hematology, biochemistry, urinalysis, and coagulation. Number of participants with clinically significant changes from baseline in laboratory values which were deemed clinically significant by the investigator were reported.
Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital signs included oral body temperature, height, weight, systolic blood pressure, diastolic blood pressure, and pulse rate. Number of participants with clinically significant changes from baseline in Vital signs which were deemed clinically significant by the investigator were reported.
Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings
Single 12-lead ECG was obtained as outlined using an ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT intervals. Number of participants with clinically significant changes from baseline in ECG which were deemed clinically significant by the investigator were reported.
Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase.
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717
Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717
AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12 and 24 hours post-dose
Area Under the Blood Concentration-Time Curve From Time Zero to 168 Hours Post-dose (AUC 0-168) of M5717
AUC from time zero to 168 hours post dose. Calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120 and 168 hours post-dose
Maximum Observed Blood Concentration (Cmax) of M5717
Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Blood Concentration at 24 Hours (C24) of M5717
Blood samples for PK analysis of C24 of M5717 was reported.
Time frame: At 24 hours post-dose
Blood Concentration at 168 Hours (C168) of M5717
C168 is the calculated blood concentration at 168 hours post-dose at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ).
Time frame: At 168 hours post-dose
Time to Reach Maximum Blood Concentration (Tmax) of M5717
Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Apparent Terminal Half-life (t1/2) of M5717
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Elimination Rate Constant (Lambda z) of M5717
Elimination rate constant determined from the terminal slope of the log-transformed concentration curve using linear regression on terminal data points of the curve.
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Apparent Total Body Clearance From Blood (CL/f) of M5717
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from blood, CL= Dose/AUC0-inf
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717
The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z).
Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
| Milestone | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 3 | 6 | 6 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 6 | 3 | 6 | 6 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with positive parasitemia defined as first positive quantitative polymerase chain reaction (qPCR) outcome equal or greater than 100 asexual parasites per milliliter (mL) of blood within 28 days of PfSPZ challenge.
| Participants | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|
| Early Liver Stage: Number of Participants Over Time With Positive Parasitemia | 6 | 3 | 2 | 1 | 0 | 0 |
Number of participants with positive parasitemia defined as first positive quantitative polymerase chain reaction (qPCR) outcome equal or greater than 100 asexual parasites per milliliter (mL) of blood within 28 days of PfSPZ challenge.
| Participants | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|
| Late Liver Stage: Number of Participants Over Time With Positive Parasitemia | 3 | 0 | 0 | 0 |
Time to first positive parasitemia was defined as the time (i.e., number of days) from the PfSPZ DVI (i.e., date of DVI PfSPZ) to the first qPCR outcome greater than or equal to (\>=) 100 asexual parasites per milliliter (mL) of blood.
| Days | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|
| Early Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR) | 10.0 (9 to 12) | 15.0 (15 to 18) | 22.0 (20 to 24) | 24.0 (24 to 24) | — | — |
Time to first positive parasitemia was defined as the time (i.e., number of days) from the PfSPZ DVI (i.e., date of DVI PfSPZ) to the first qPCR outcome greater than or equal to (\>=) 100 asexual parasites per milliliter (mL) of blood.
| Days | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|
| Late Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR) | 10.0 (9 to 11) | — | — | — |
Documented blood stage parasite growth was defined as an increase of qPCR measured asexual parasites per mL compared to the first parasitemia measurement, within 28 days of PfSPZ DVI.
| Participants | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|
| Early Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth | 5 | 2 | 2 | 1 | 0 | 0 |
Documented blood stage parasite growth was defined as an increase of qPCR measured asexual parasites per mL compared to the first parasitemia measurement, within 28 days of PfSPZ DVI.
| Participants | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|
| Late Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth | 3 | 0 | 0 | 0 |
The malaria clinical score consisted of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension. The minimum score was 0 (no symptoms) and the maximum score was 42 (maximum symptoms). Total scores are reported here.
| score on a Scale | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|
| At Day 6 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.1 ± 0.30 |
| At Day 7 | 0.3 ± 0.52 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 8 | 0.2 ± 0.41 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 9 | 0.2 ± 0.41 | 0.3 ± 0.58 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 10 | 0.3 ± 0.52 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.3 ± 0.52 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 11 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 12 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 13 | 1.7 ± 1.86 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 14 | 4.5 ± 3.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 15 | 1.5 ± 2.07 | 0.0 ± 0.00 | 0.2 ± 0.41 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 16 | 2.0 ± 1.41 | 0.3 ± 0.58 | 0.3 ± 0.52 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 17 | 0.5 ± 0.71 | 2.0 ± 3.46 | 0.3 ± 0.52 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 18 | 1.0 ± 1.41 | 2.3 ± 4.04 | 0.3 ± 0.52 | 0.2 ± 0.41 | 0.3 ± 0.58 | 0.3 ± 0.58 |
| At Day 19 | — | 0.7 ± 1.15 | 0.3 ± 0.52 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 |
| At Day 20 | — | 1.0 ± 1.73 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 |
| At Day 22 | 0.0 ± 0.00 | 0.7 ± 1.15 | 0.0 ± 0.00 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 24 | — | — | 0.0 ± 0.00 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 26 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.2 ± 0.41 | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.3 ± 0.58 |
| At Day 28 | 0.0 ± 0.0 | 0.0 ± 0.00 | 0.2 ± 0.41 | 0.2 ± 0.41 | 0.3 ± 0.58 | 0.0 ± 0.00 |
The malaria clinical score consisted of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension. The minimum score was 0 (no symptoms) and the maximum score was 42 (maximum symptoms). Total scores are reported here.
| Score on a Scale | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|
| At Day 6 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 7 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 8 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 |
| At Day 9 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 |
| At Day 10 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 11 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 12 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 13 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 14 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 |
| At Day 15 | 1.5 ± 2.12 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.3 ± 0.58 |
| At Day 16 | 1.5 ± 2.12 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 17 | 1.0 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.7 ± 1.15 |
| At Day 18 | — | 0.3 ± 0.58 | 0.3 ± 0.58 | 0.0 ± 0.00 |
| At Day 19 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 |
| At Day 20 | — | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.0 ± 0.00 |
| At Day 21 | — | 0.3 ± 0.58 | 0.3 ± 0.58 | 0.3 ± 0.58 |
| At Day 22 | — | 0.0 ± 0.00 | 0.3 ± 0.58 | 0.3 ± 0.58 |
| At Day 23 | — | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.3 ± 0.58 |
| At Day 24 | — | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 26 | 0.3 ± 0.58 | 0.3 ± 0.58 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 28 | — | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| At Day 30 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.00 ± 0.00 |
| At Day 32 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE was defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment-related TEAEs: reasonably related to study intervention.
| Participants | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|---|---|
| Participants with TEAEs | 5 | 3 | 6 | 6 | 3 | 3 | 3 | 3 | 2 | 2 |
| Participants with Serious TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with Treatment-related TEAEs | 2 | 0 | 2 | 2 | 1 | 3 | 0 | 1 | 0 | 0 |
Severity of adverse events (AE) were assessed by the investigator per the Qualitative Toxicity Scale. Grade 1= Mild, Grade 2=Moderate, Grade 3=Severe. The number of participants that experienced at least one solicited local TEAE were summarized by grade. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of participants with Grade=1, Grade=2 and 3 were reported.
| Participants | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 (Mild) | 5 | 3 | 6 | 6 | 3 | 3 | 3 | 3 | 2 | 2 |
| Grade 2 (Moderate) | 3 | 2 | 2 | 1 | 0 | 1 | 2 | 0 | 0 | 0 |
| Grade 3 (Severe) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
Laboratory assessments included hematology, biochemistry, urinalysis, and coagulation. Number of participants with clinically significant changes from baseline in laboratory values which were deemed clinically significant by the investigator were reported.
| Participants | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs included oral body temperature, height, weight, systolic blood pressure, diastolic blood pressure, and pulse rate. Number of participants with clinically significant changes from baseline in Vital signs which were deemed clinically significant by the investigator were reported.
| Participants | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Single 12-lead ECG was obtained as outlined using an ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT intervals. Number of participants with clinically significant changes from baseline in ECG which were deemed clinically significant by the investigator were reported.
| Participants | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase.
| hour*nanogram per milliliter(hour*ng/mL) | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717 | — | 1280 ± 31.81 | 1990 ± 25.24 | 1890 ± 12.52 | 9840 ± 37.44 | 1100 ± 71.03 | 2330 ± 4.70 | 4830 ± 53.73 |
Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
| hour*ng/mL | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717 | 21.9 ± 1160.32 | 852 ± 36.35 | 1270 ± 14.08 | 1470 ± 4.65 | 7330 ± 42.80 | 657 ± 67.17 | 1810 ± 8.09 | 3820 ± 70.38 |
AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
| h*ng/mL | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717 | 25.8 ± 639.59 | 198 ± 40.21 | 280 ± 18.23 | 290 ± 39.80 | 975 ± 33.02 | 160 ± 44.63 | 445 ± 8.60 | 1020 ± 45.85 |
AUC from time zero to 168 hours post dose. Calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.
| h*ng/mL | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Area Under the Blood Concentration-Time Curve From Time Zero to 168 Hours Post-dose (AUC 0-168) of M5717 | 50.4 ± 2325.31 | 805 ± 35.22 | 1190 ± 14.35 | 1390 ± 5.34 | 3680 ± 29.33 | 692 ± 53.24 | 1710 ± 8.67 | 3190 ± 43.40 |
Cmax was obtained directly from the concentration versus time curve.
| nanogram per milliliter (ng/mL) | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Maximum Observed Blood Concentration (Cmax) of M5717 | 3.56 ± 39.90 | 11.7 ± 36.93 | 16.6 ± 33.70 | 17.2 ± 44.12 | 57.2 ± 38.08 | 9.38 ± 82.50 | 27.6 ± 22.19 | 64.4 ± 46.26 |
Blood samples for PK analysis of C24 of M5717 was reported.
| ng/mL | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Blood Concentration at 24 Hours (C24) of M5717 | NA ± NA | 6.77 ± 45.35 | 9.42 ± 28.12 | 11.3 ± 31.42 | 30.6 ± 24.91 | 6.06 ± 37.89 | 14.9 ± 14.56 | 26.7 ± 37.88 |
C168 is the calculated blood concentration at 168 hours post-dose at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ).
| ng/mL | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Blood Concentration at 168 Hours (C168) of M5717 | NA ± NA | 2.89 ± 38.61 | 4.31 ± 13.43 | 4.16 ± 24.60 | 11.4 ± 40.64 | NA ± NA | 4.88 ± 2.50 | 8.30 ± 45.60 |
Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.
| Hours | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Blood Concentration (Tmax) of M5717 | 6.00 (0.500 to 12.0) | 1.00 (0.500 to 12.0) | 3.25 (0.500 to 12.0) | 6.00 (0.500 to 12.0) | 1.00 (0.500 to 6.00) | 1.00 (0.500 to 1.00) | 2.00 (1.00 to 2.02) | 2.00 (2.00 to 2.00) |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
| Hours | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of M5717 | — | 121 (82.3 to 143) | 121 (97.2 to 221) | 66.9 (66.6 to 108) | 494 (212 to 531) | 94.1 (74.2 to 156) | 95.4 (76.0 to 95.5) | 136 (101 to 183) |
Elimination rate constant determined from the terminal slope of the log-transformed concentration curve using linear regression on terminal data points of the curve.
| One per Hours (1/h) | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Elimination Rate Constant (Lambda z) of M5717 | — | 0.00597 ± 22.93 | 0.00529 ± 30.44 | 0.00885 ± 28.59 | 0.00182 ± 55.45 | 0.00677 ± 38.43 | 0.00786 ± 12.78 | 0.00511 ± 30.50 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from blood, CL= Dose/AUC0-inf
| Liter per Hours (L/h) | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Apparent Total Body Clearance From Blood (CL/f) of M5717 | — | 46.9 ± 31.81 | 40.3 ± 25.24 | 52.9 ± 12.52 | 20.3 ± 37.44 | 54.8 ± 71.03 | 43.0 ± 4.70 | 41.4 ± 53.73 |
The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z).
| Liter | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717 | — | 7850 ± 42.71 | 7600 ± 10.87 | 5980 ± 15.57 | 11200 ± 60.47 | 8130 ± 35.29 | 5490 ± 15.71 | 27.59 ± 8340 |
Exposure efficacy relationship was analyzed using logistic regression model. Different exposure matrices (AUC0-24, AUC0-168, AUC0-inf, C24 and C168) were analyzed using logistic regression model.
| slope | All Participants: AUC0-24 | All Participants: AUC0-168 | All Participants: AUC0-inf | All Participants: C24 | All Participants: C168 |
|---|---|---|---|---|---|
| Dose Exposure Response Relationship of M5717 Assessed by Logistic Regression Model | 1.27 | 1.43 | 1.44 | 0.800 | 2.45 |
Collected over Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Early Liver Stage: Pooled Placebo | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Early Liver Stage: 30 mg M5717 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Early Liver Stage: 60 mg M5717 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Early Liver Stage: 80 mg M5717 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Early Liver Stage: 100 mg M5717 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Early Liver Stage: 200 mg M5717 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Late Liver Stage: Pooled Placebo | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Late Liver Stage: 60 mg M5717 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Late Liver Stage: 100 mg M5717 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Late Liver Stage: 200 mg M5717 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Event | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 |
|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/6 | 0/3 | 1/6 | 2/6 | 3/3 | 2/3 | 2/3 | 1/3 | 1/3 | 0/3 |
| NauseaGastrointestinal disorders | 4/6 | 0/3 | 4/6 | 1/6 | 2/3 | 1/3 | 3/3 | 2/3 | 1/3 | 2/3 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/6 | 3/3 | 4/6 | 3/6 | 1/3 | 1/3 | 0/3 | 2/3 | 1/3 | 1/3 |
| FatigueGeneral disorders | 3/6 | 2/3 | 1/6 | 0/6 | 1/3 | 0/3 | 1/3 | 3/3 | 0/3 | 1/3 |
| HeadacheNervous system disorders | 4/6 | 2/3 | 3/6 | 3/6 | 2/3 | 2/3 | 2/3 | 0/3 | 1/3 | 1/3 |
| DizzinessNervous system disorders | 3/6 | 0/3 | 1/6 | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 |
| Abdominal discomfortGastrointestinal disorders | 2/6 | 0/3 | 1/6 | 1/6 | 0/3 | 0/3 | 1/3 | 0/3 | 1/3 | 0/3 |
| Abdominal distensionGastrointestinal disorders | 1/6 | 1/3 | 0/6 | 0/6 | 1/3 | 1/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/3 | 0/6 | 1/6 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 |
| VomitingGastrointestinal disorders | 1/6 | 0/3 | 0/6 | 0/6 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
Safety analysis population (SAF) included all intent to treat (ITT) participants, who have been inoculated using a Direct Intravenous Inoculation (DVI) of PfSPZ and who were administered one dose of study intervention (M5717 or placebo). ITT population included all participants, who were randomized to study intervention.
| Age, Categorical(Participants) | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 3 | 6 | 6 | 3 | 3 | 3 | 3 | 3 | 3 | 39 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 2 | 3 | 0 | 0 | 2 | 1 | 2 | 1 | 11 |
| Male | 6 | 3 | 4 | 3 | 3 | 3 | 1 | 2 | 1 | 2 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 3 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 3 | 38 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Early Liver Stage: Pooled Placebo | Early Liver Stage: 30 mg M5717 | Early Liver Stage: 60 mg M5717 | Early Liver Stage: 80 mg M5717 | Early Liver Stage: 100 mg M5717 | Early Liver Stage: 200 mg M5717 | Late Liver Stage: Pooled Placebo | Late Liver Stage: 60 mg M5717 | Late Liver Stage: 100 mg M5717 | Late Liver Stage: 200 mg M5717 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| White | 5 | 3 | 6 | 5 | 3 | 2 | 3 | 2 | 3 | 3 | 35 |
| More than one race | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Ran from Feb 2020 to primary completion in Aug 2021, 18 months.
Results were first posted in May 2024, 2 years 8 months after primary completion.
Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 18 months is above that.
Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabamiquine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →